Pulmonx Co. (NASDAQ:LUNG) Director Sells $459,150.84 in Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 55,453 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $8.28, for a total value of $459,150.84. Following the completion of the transaction, the director now owns 1,011,974 shares in the company, valued at $8,379,144.72. This represents a 5.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pulmonx Stock Down 0.4 %

LUNG stock traded down $0.04 during mid-day trading on Monday, hitting $8.92. 597,603 shares of the company were exchanged, compared to its average volume of 342,603. The firm has a market cap of $352.25 million, a P/E ratio of -6.19 and a beta of 0.64. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $11.10. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The firm’s 50 day simple moving average is $6.53 and its 200 day simple moving average is $6.79.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.12. The business had revenue of $23.77 million for the quarter, compared to analysts’ expectations of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. On average, sell-side analysts predict that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. SG Americas Securities LLC bought a new position in shares of Pulmonx during the 3rd quarter worth approximately $102,000. GSA Capital Partners LLP acquired a new position in Pulmonx during the third quarter worth $537,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Pulmonx in the third quarter valued at $480,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Pulmonx by 5.2% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company’s stock valued at $9,238,000 after buying an additional 55,279 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Pulmonx by 5.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 313,169 shares of the company’s stock worth $2,596,000 after buying an additional 15,543 shares in the last quarter. 91.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LUNG. Citigroup restated a “neutral” rating and set a $7.50 target price (down previously from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Stifel Nicolaus cut their price target on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Finally, Wells Fargo & Company decreased their price objective on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.75.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.